These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 19826039)
21. Changes in CXCL12/CXCR4-chemokine expression during onset of colorectal malignancies. Oliveira Frick V; Rubie C; Ghadjar P; Faust SK; Wagner M; Gräber S; Schilling MK Tumour Biol; 2011 Feb; 32(1):189-96. PubMed ID: 20865359 [TBL] [Abstract][Full Text] [Related]
22. Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. Heist RS; Duda DG; Sahani DV; Ancukiewicz M; Fidias P; Sequist LV; Temel JS; Shaw AT; Pennell NA; Neal JW; Gandhi L; Lynch TJ; Engelman JA; Jain RK Proc Natl Acad Sci U S A; 2015 Feb; 112(5):1547-52. PubMed ID: 25605928 [TBL] [Abstract][Full Text] [Related]
23. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy. Arimura N; Otsuka H; Yamakiri K; Sonoda Y; Nakao S; Noda Y; Hashiguchi T; Maruyama I; Sakamoto T Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951 [TBL] [Abstract][Full Text] [Related]
24. Current status and perspective of angiogenesis and antivascular therapeutic strategy: non-small cell lung cancer. Yano S; Matsumori Y; Ikuta K; Ogino H; Doljinsuren T; Sone S Int J Clin Oncol; 2006 Apr; 11(2):73-81. PubMed ID: 16622742 [TBL] [Abstract][Full Text] [Related]
25. Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients. Oliveira AM; Maria DA; Metzger M; Linardi C; Giorgi RR; Moura F; Martinez GA; Bydlowski SP; Novak EM Leuk Res; 2009 Jul; 33(7):970-3. PubMed ID: 18976811 [TBL] [Abstract][Full Text] [Related]
26. Vascular endothelial growth factor and bevacitumab in breast cancer. Bando H Breast Cancer; 2007; 14(2):163-73. PubMed ID: 17485901 [TBL] [Abstract][Full Text] [Related]
27. AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors. Watanabe M; Boyer JL; Crystal RG Gene Ther; 2010 Aug; 17(8):1042-51. PubMed ID: 20596059 [TBL] [Abstract][Full Text] [Related]
28. Identification and significance of mobilized endothelial progenitor cells in tumor neovascularization of renal cell carcinoma. Yu P; Ge YZ; Zhao Y; Wu JP; Wu R; Zhou LH; Jia RP Tumour Biol; 2014 Sep; 35(9):9331-41. PubMed ID: 24943683 [TBL] [Abstract][Full Text] [Related]
29. Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2. Kernt M; Thiele S; Neubauer AS; Koenig S; Hirneiss C; Haritoglou C; Ulbig MW; Kampik A Retina; 2012 Sep; 32(8):1652-63. PubMed ID: 22466477 [TBL] [Abstract][Full Text] [Related]
30. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. Siegel AB; Cohen EI; Ocean A; Lehrer D; Goldenberg A; Knox JJ; Chen H; Clark-Garvey S; Weinberg A; Mandeli J; Christos P; Mazumdar M; Popa E; Brown RS; Rafii S; Schwartz JD J Clin Oncol; 2008 Jun; 26(18):2992-8. PubMed ID: 18565886 [TBL] [Abstract][Full Text] [Related]
31. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts. Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080 [TBL] [Abstract][Full Text] [Related]
32. Notch pathway promotes ovarian cancer growth and migration via CXCR4/SDF1α chemokine system. Chiaramonte R; Colombo M; Bulfamante G; Falleni M; Tosi D; Garavelli S; De Simone D; Vigolo E; Todoerti K; Neri A; Platonova N Int J Biochem Cell Biol; 2015 Sep; 66():134-40. PubMed ID: 26235278 [TBL] [Abstract][Full Text] [Related]
33. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. Grothey A; Ellis LM Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556 [TBL] [Abstract][Full Text] [Related]
34. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197 [TBL] [Abstract][Full Text] [Related]
35. Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. Rangwala F; Bendell JC; Kozloff MF; Arrowood CC; Dellinger A; Meadows J; Tourt-Uhlig S; Murphy J; Meadows KL; Starr A; Broderick S; Brady JC; Cushman SM; Morse MA; Uronis HE; Hsu SD; Zafar SY; Wallace J; Starodub AN; Strickler JH; Pang H; Nixon AB; Hurwitz HI Invest New Drugs; 2014 Aug; 32(4):700-9. PubMed ID: 24711126 [TBL] [Abstract][Full Text] [Related]
36. Hepatic stellate cells promote liver metastasis of colon cancer cells by the action of SDF-1/CXCR4 axis. Matsusue R; Kubo H; Hisamori S; Okoshi K; Takagi H; Hida K; Nakano K; Itami A; Kawada K; Nagayama S; Sakai Y Ann Surg Oncol; 2009 Sep; 16(9):2645-53. PubMed ID: 19588204 [TBL] [Abstract][Full Text] [Related]
37. VEGF pathway-targeting drugs induce evasive adaptation by activation of neuropilin-1/cMet in colon cancer cells. Tomida C; Yamagishi N; Nagano H; Uchida T; Ohno A; Hirasaka K; Nikawa T; Teshima-Kondo S Int J Oncol; 2018 Apr; 52(4):1350-1362. PubMed ID: 29532881 [TBL] [Abstract][Full Text] [Related]
38. Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma. Yang H; Jager MJ; Grossniklaus HE Invest Ophthalmol Vis Sci; 2010 Jun; 51(6):2835-42. PubMed ID: 20089875 [TBL] [Abstract][Full Text] [Related]
39. Feasibility of anti-VEGF agent bevacizumab in patients with Crohn's disease. Coriat R; Mir O; Leblanc S; Ropert S; Brezault C; Chaussade S; Goldwasser F Inflamm Bowel Dis; 2011 Jul; 17(7):1632. PubMed ID: 21674721 [No Abstract] [Full Text] [Related]
40. The CXCL12-CXCR4 chemokine pathway: a novel axis regulates lymphangiogenesis. Zhuo W; Jia L; Song N; Lu XA; Ding Y; Wang X; Song X; Fu Y; Luo Y Clin Cancer Res; 2012 Oct; 18(19):5387-98. PubMed ID: 22932666 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]